News and Events

Patients more willing to pay for combination immunotherapy than BRAF/MEK inhibitors due to overall survival expectations

11 February 2019

Melanoma patients’ who are receiving immunotherapy and targeted therapyhave different perceptions about quality of life expectations, degree of anxiety and progression-free survival differ compared with their provider, according to this  recent study. The study also suggests patients and providers exhibit a higher willingness to pay for combination immunotherapy treatment compared with BRAF/MEK inhibitors, influenced predominately by overall survival expectations.

Dung beetle glycosaminoglycan decreases melanoma size in mice

11 January 2019

Administration of dung beetle glycosaminoglycan, CaG increased survival time and decreased melanoma sizes in mice, in accordance with their inhibitory effects on cell growth ratio of melanoma B16F10, according to this recent study.